EVMN — Evommune, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2044725 ·
Last close
$11.25
Market Cap
$405.21M
52W High
$25.87
52W Low
$10.47
ADV30
1,143,641
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -23,954,000 | -21,674,000 | 322,455,000 | 48,318,000 | 17,900,000 |
| Dec 2025 | 0 | — | -29,716,000 | -28,273,000 | 224,946,000 | 44,063,000 | 19,380,000 |
| Sep 2025 | 10,000,000 | — | -13,328,000 | -12,475,000 | 84,544,000 | 26,818,000 | 267,681,000 |
| Dec 2024 | 0 | — | -21,454,000 | -20,726,000 | 76,055,000 | 16,255,000 | 220,292,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,073,000
Investing CF
$-170,475,000
Financing CF
$206,161,000
CapEx
$-104,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.84
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-221,089,000
Inventory
—
Receivables
—
ST Investments
$105,137,000
EBIT TTM
$-81,015,000
Pretax Income TTM
$-77,390,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,000,000
EBITDA
$-88,632,000
Free Cash Flow
$-57,526,500
Enterprise Value
$206,458,528
Total Cash
$211,464,000
Total Debt
$9,114,000
Shares Out
36,018,372
Trailing EPS
$-2.11
Book Value
$8.46
ROE
-45.0%
ROA
-29.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,000,000 | -81,071,000 | -68,870,000 | 224,946,000 | 19,380,000 | — | -76,441,000 |
| Dec 2024 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | $403.63M | $7.93 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $408.11M | $0.38 | — |
| BNTC | Benitec Biopharma Inc. | $402.29M | $11.71 | — |
| BIOA | BioAge Labs, Inc. | $401.85M | $9.04 | — |
| KMDA | KAMADA LTD | $411.94M | $7.14 | — |
News headlines (Yahoo Finance, 1h cache)
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
2026-07-30 12:00 · Yahoo
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
2026-06-30 15:15 · Yahoo
Evommune terminates oral drug’s development in CSU
2026-06-29 15:28 · Yahoo
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
2026-06-29 14:16 · Yahoo
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
2026-05-11 12:05 · Yahoo
Evommune bucked biotech IPO drought and is focused on the long game
2026-04-07 08:00 · Yahoo
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says
2026-04-10 15:45 · Yahoo
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
2026-06-08 11:16 · Yahoo
Biotech’s IPO comeback; Trump’s tariff loophole for pharma
2026-04-10 08:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.